Trulicity Patient Assistance for Low-Income: How Women Can Get Dulaglutide Without Paying Full Price

Why Trulicity Is So Expensive and Why Women Bear More of the Burden

Trulicity's list price sits near $931 per month for the standard four-pen supply, a figure that reflects both the cost of manufacturing GLP-1 receptor agonist biologics and the absence of a generic competitor. Eli Lilly's published list price places dulaglutide among the most expensive non-insulin diabetes medications on the market.

Women face a specific financial disadvantage here. PCOS affects roughly 8 to 13 percent of women of reproductive age globally, and a significant proportion of these women have insulin resistance that GLP-1 receptor agonists like dulaglutide can address. Yet dulaglutide is not FDA-approved for PCOS or weight management in the same way semaglutide (Ozempic, Wegovy) is, meaning insurers frequently deny coverage when PCOS is listed as the primary diagnosis rather than type 2 diabetes. That gap pushes many women toward cash pay or expensive compounding pharmacies.

Postmenopausal women face a different barrier. Metabolic disease risk rises sharply after estrogen loss, making GLP-1 therapy more medically relevant, but women in this group often have fixed incomes or rely on Medicare, which historically has restricted GLP-1 coverage. The Inflation Reduction Act's Medicare drug price negotiation framework is beginning to shift this, but coverage gaps remain in 2026.

The bottom line: the system was not designed with you in mind. The strategies below are organized by insurance status so you can go directly to what applies to your situation.

The Lilly Cares Foundation Patient Assistance Program

The Lilly Cares Foundation is Eli Lilly's nonprofit patient assistance arm. If you meet the income and residency criteria, you may receive Trulicity at no cost or at a significantly reduced cost directly from Lilly.

Who Qualifies

To be eligible in 2026, you generally need to meet all three of the following conditions:

• You are a U.S. Resident.
• You are uninsured, underinsured, or your insurance does not cover Trulicity.
• Your household income falls at or below approximately 400% of the federal poverty level (FPL). For a single person in 2025, 400% FPL is roughly $60,240 per year. Lilly adjusts thresholds periodically, so verify the current figure at the time you apply.

Income limits may be higher for larger households. Lilly sometimes grants exceptions for patients with high medical expenses relative to income, so a denial is not always final.

How to Apply

The application process has three steps.

1. Your prescribing clinician fills out a section of the application confirming your diagnosis and prescription.
2. You provide proof of income (tax return, pay stubs, or a self-attestation form if undocumented income applies).
3. You submit the completed application by fax, mail, or through your clinician's office. Some practices use specialty pharmacy software that connects directly to Lilly's system.

Processing takes two to four weeks on average. Once approved, medication is typically shipped directly to your prescriber's office or, in some states, to your home. Enrollment is not permanent; you re-certify annually.

Because program rules change, confirm current eligibility criteria directly with Lilly Cares at 1-800-545-5979 or through a patient advocate at your clinic before spending time gathering documents.

Women-Specific Considerations for This Program

If your Trulicity is prescribed for PCOS-related insulin resistance rather than type 2 diabetes, some Lilly Cares reviewers may flag the application. Ask your clinician to document your diagnosis using the ICD-10 code for type 2 diabetes mellitus (E11.x) if that also applies, or to write a detailed letter of medical necessity explaining the insulin-resistance mechanism. This does not guarantee approval but it addresses the most common reason for a hold.

The Lilly Insulin Value Program and Copay Card for Commercially Insured Patients

If you have private insurance (employer-sponsored, ACA marketplace plan, or individual coverage), the Lilly Trulicity copay card can reduce your monthly out-of-pocket cost to as little as $25 per fill, with some caps on annual savings.

How the Copay Card Works

The copay card functions as a secondary payer. You pay your copay, and Lilly covers the remaining cost up to a set annual cap (currently around $5,200 per year, though this figure changes). After the cap is reached, you pay your normal insurance cost for the rest of the year.

To use the card:

• Enroll at Lilly's savings portal or ask your pharmacist to look up the copay card at point of sale.
• Present the card like a secondary insurance card at a participating retail pharmacy.
• The discount applies only to brand-name Trulicity; it does not apply at pharmacies that do not accept copay cards.

What Doesn't Qualify

Federal law bars the use of manufacturer copay cards if your prescription is covered by Medicare, Medicaid, or any other federally funded program. Using a copay card under those programs is considered a kickback violation. If you are on Medicare or Medicaid, skip to the sections below.

Medicare and Trulicity: Your Real Options in 2026

Medicare coverage for GLP-1 receptor agonists has been expanding, but it remains inconsistent. Here is where things stand.

Medicare Part D Coverage

Most Part D plans cover Trulicity when prescribed for type 2 diabetes. Coverage for weight management indications varies by plan and is still evolving following the American Diabetes Association's 2024 Standards of Care, which strongly emphasize GLP-1 agents as first- or second-line therapy for people with type 2 diabetes and cardiovascular risk.

Your out-of-pocket cost under Part D depends on your plan tier placement. Trulicity typically lands on Tier 4 or 5 (specialty tier), which means coinsurance rather than a flat copay, often 25 to 33 percent of the negotiated cost.

Low Income Subsidy (Extra Help)

The Social Security Administration's Extra Help program, also called the Low Income Subsidy (LIS), can reduce your Part D cost-sharing to as little as a few dollars per fill. SSA estimates that Extra Help saves enrollees an average of $5,300 per year on prescription costs. You may qualify if your income is at or below 150% FPL and your assets are below SSA's limit (currently around $17,220 for an individual in 2025).

Apply through the Social Security Administration online or by calling 1-800-772-1213.

Medicare Advantage Plans

Some Medicare Advantage (Part C) plans have negotiated lower specialty drug tiers for GLP-1s. If you are approaching your annual open enrollment window, it is worth comparing plans using the Medicare Plan Finder specifically filtering on Trulicity's tier placement.

Medicaid Coverage for Trulicity

Medicaid coverage for dulaglutide differs by state. Most state Medicaid programs cover Trulicity for type 2 diabetes but may require prior authorization, step therapy (trying metformin or a sulfonylurea first), or an HbA1c threshold above a certain level before approval.

If your state Medicaid denies Trulicity, you have the right to appeal. Your prescriber can submit a peer-to-peer review or a letter of medical necessity. ACOG's clinical guidance on diabetes in pregnancy and the ADA Standards of Care are useful references for your clinician to cite in appeals.

Women with PCOS on Medicaid face the same documentation challenge described above: the diagnosis must be framed in a way that matches covered indications. A combined diagnosis of type 2 diabetes and PCOS strengthens the case.

Other Ways to Lower Your Trulicity Cost

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) does not currently carry Trulicity because dulaglutide has no generic form. This option is not available as of early 2026, but it is worth checking periodically as the platform expands.

GoodRx and Discount Cards

GoodRx and similar discount cards do not typically bring Trulicity's cash price below $800 to $900 at major retail pharmacies. These cards are most useful for generic medications. For Trulicity, Lilly's own programs almost always produce a better result if you qualify.

340B-Covered Health Centers

Federally Qualified Health Centers (FQHCs) and some hospitals that qualify for the 340B Drug Pricing Program can purchase dulaglutide at a steep discount and may pass some of that savings to uninsured or low-income patients. If you live near an FQHC or a safety-net hospital, ask whether their on-site pharmacy dispenses Trulicity under 340B pricing.

Telehealth-Compounded GLP-1 Alternatives

Compounded semaglutide and tirzepatide have been available through telehealth platforms at far lower prices, sometimes under $200 per month, but FDA policy on compounding has been evolving rapidly in 2025 and 2026. Compounded dulaglutide is not widely available because dulaglutide is a more complex peptide structure than semaglutide. If cost is the primary barrier and you are considering a compounded GLP-1, semaglutide or tirzepatide compounded products may be a separate conversation with your clinician, not Trulicity specifically.

Pregnancy, Lactation, and Contraception: What Every Woman Using Trulicity Must Know

This section is required reading if you are of reproductive age, planning a pregnancy, or currently pregnant or breastfeeding.

Trulicity Is Contraindicated in Pregnancy

Dulaglutide is classified as Pregnancy Category not formally reassigned under the newer labeling system, but the FDA-approved Trulicity label states that animal studies showed adverse fetal effects at clinically relevant exposures, and human safety data in pregnancy is extremely limited. The label advises discontinuing Trulicity at least two months before a planned pregnancy.

If you become pregnant while taking Trulicity, stop the medication and contact your clinician the same day. Ongoing exposure is not considered safe based on current evidence.

Contraception Is Required

Because dulaglutide has a long half-life of approximately five days and because the drug's effects on fetal development are unknown in humans, reliable contraception is recommended throughout the course of treatment. If you are using hormonal contraception, be aware that GLP-1 receptor agonists slow gastric emptying, which could theoretically reduce absorption of oral contraceptive pills taken at the same time, though a pharmacokinetic study published in Clinical Pharmacokinetics found that dulaglutide did not significantly alter ethinyl estradiol or norgestimate exposure when taken together. Still, if you vomit within two hours of taking an oral contraceptive pill due to dulaglutide-related nausea, treat that day as a missed pill per your contraceptive instructions.

Long-acting reversible contraception (IUD or implant) avoids this concern entirely.

Lactation

No human data exists on dulaglutide transfer into breast milk. The molecular weight of the peptide is large, which theoretically limits transfer, but the FDA label advises caution and shared decision-making with your clinician. Because dulaglutide is used for chronic metabolic conditions and is not considered an acute necessity in the same way as an antibiotic, most clinicians recommend pausing it during lactation and revisiting after weaning. LactMed, the NIH's database for drugs in breast milk, currently lists dulaglutide as having insufficient data to assess safety.

Perimenopause and Post-Menopause

Women in perimenopause and post-menopause often develop insulin resistance as estrogen declines, and dulaglutide may be appropriate in this life stage for type 2 diabetes management or cardiovascular risk reduction. The REWIND trial, which studied dulaglutide 1.5 mg weekly in adults with type 2 diabetes and cardiovascular risk factors, enrolled women at a rate of about 46 percent, with a mean age of 66 years. Over a median of 5.4 years, dulaglutide reduced the composite of major adverse cardiovascular events by 12 percent compared to placebo. This is one of the stronger GLP-1 cardiovascular datasets and is particularly relevant for postmenopausal women with type 2 diabetes and established or at-risk cardiovascular disease.

The WomanRx framework for approaching Trulicity access by life stage:

| Life Stage | Key Access Consideration | Clinical Note | |---|---|---| | Reproductive years, no diabetes | Insurance may deny; PCOS framing needed | Reliable contraception required | | Trying to conceive | Discontinue 2 months before attempting | Switch to pregnancy-compatible diabetes management | | Pregnant | Contraindicated. Stop immediately | Insulin is the preferred option | | Postpartum / breastfeeding | Insufficient lactation data; pause advised | Revisit after weaning | | Perimenopause | Rising cardiovascular risk makes coverage argument stronger | Cardiovascular indication may help prior auth | | Post-menopause | Medicare may apply; REWIND data supports use | Extra Help if income-eligible |

Who Trulicity Is Right For and Who Should Look at Other Options

Trulicity may be a good fit if you:

• Have type 2 diabetes and prefer a once-weekly injectable over daily medications.
• Have type 2 diabetes and an elevated cardiovascular risk, given the REWIND cardiovascular outcome data.
• Have PCOS with confirmed insulin resistance and your clinician has documented the clinical rationale.
• Tolerate the GI side effects of GLP-1 medications (nausea and diarrhea are the most common, each affecting roughly 10 to 20 percent of patients in the REWIND trial).
• Are postmenopausal with new-onset metabolic disease.

Trulicity may not be the right choice if you:

• Are pregnant or actively trying to conceive within the next two months.
• Are breastfeeding and unwilling to pause.
• Have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, both of which are contraindications listed in the FDA prescribing information.
• Need a medication covered by your specific insurance plan and Trulicity is not on formulary.
• Are on Medicare and cannot afford the Part D cost-sharing even with Extra Help.

How to Talk to Your Clinician About Access and Affordability

Many women avoid bringing up cost because they feel it reflects poorly on them or they assume the clinician cannot help. Clinicians who prescribe Trulicity regularly have dealt with insurance denials and prior authorizations hundreds of times. Saying directly, "I can't afford the out-of-pocket cost and I need help finding a program" is the fastest way to get practical help.

Specific language that tends to move things forward:

• "Can your office submit a prior authorization with the insulin resistance / cardiovascular risk documentation?"
• "Do you have a sample pen I can use while the assistance paperwork is being processed?"
• "Can you write a letter of medical necessity for my insurance appeal?"

Ask your clinician's office whether they have a dedicated patient navigator or a pharmacy liaison. Larger practices and health systems often do.

Trulicity and Women's Conditions Beyond Diabetes

PCOS

Roughly half of women with PCOS have insulin resistance, and improving insulin sensitivity is a central treatment goal because hyperinsulinemia drives excess androgen production. GLP-1 receptor agonists, including dulaglutide, improve insulin sensitivity by stimulating glucose-dependent insulin secretion and slowing gastric emptying. Small studies and case series suggest GLP-1 agents may improve menstrual regularity and reduce androgen levels in women with PCOS, but there are no large randomized controlled trials of dulaglutide specifically in PCOS populations. The evidence is extrapolated primarily from semaglutide and liraglutide studies. Be skeptical of any source that presents dulaglutide as a proven PCOS treatment; the data does not yet support that framing.

Female Pattern Weight Gain in Perimenopause

Visceral fat accumulation accelerates during the menopausal transition as estrogen falls. Dulaglutide has been shown to reduce body weight in people with type 2 diabetes, with the AWARD-11 trial demonstrating that the 4.5 mg dose of dulaglutide produced a mean weight loss of approximately 10.0 kg over 36 weeks compared to 6.6 kg with the 1.5 mg dose. These data came from mixed-sex populations; whether perimenopausal women respond differently is not well characterized. Women have been historically underrepresented in GLP-1 metabolic trials, and subgroup analyses by hormonal status are rarely reported. This is a genuine evidence gap.

Thyroid Monitoring

GLP-1 receptor agonists carry an FDA black-box warning about the theoretical risk of thyroid C-cell tumors based on rodent data. Women already have a three to four times higher lifetime incidence of thyroid disease than men, including autoimmune thyroiditis and differentiated thyroid cancers. The FDA label advises that patients with a personal or family history of medullary thyroid carcinoma should not use dulaglutide. For women with Hashimoto's thyroiditis or a history of thyroid nodules, this does not constitute a contraindication, but your clinician may want a baseline thyroid ultrasound if you have known nodular disease.

Step-by-Step: Getting Trulicity at the Lowest Possible Cost

1. Confirm your insurance type (commercial, Medicare Part D, Medicaid, or none).
2. If commercially insured: enroll in the Lilly copay card before your first fill. Your pharmacist or clinician's office can do this in under five minutes.
3. If uninsured or underinsured: start a Lilly Cares Foundation application at the same time your clinician sends the prescription. The two-to-four week processing window means you may need samples from your clinician's office while you wait.
4. If on Medicare Part D: apply for Extra Help through SSA if your income is at or below 150% FPL. Compare Part D plans during open enrollment using Medicare Plan Finder, filtering specifically for Trulicity's tier.
5. If on Medicaid: check your state's formulary online or call the Medicaid member services line. If prior authorization is required, ask your clinician's office to submit it with supporting ADA guideline citations.
6. If all options fail: ask your clinician about therapeutic alternatives that have broader insurance coverage (metformin, SGLT-2 inhibitors, or a different GLP-1 with better formulary placement).
7. Re-verify your assistance program annually. Both the Lilly Cares and copay card programs renew on a calendar-year basis and terms change.

Every program described here is subject to change. Verify all current eligibility, income limits, and savings amounts directly with Eli Lilly (1-800-545-5979 for Lilly Cares) or through your insurance plan before making financial decisions. As of early 2026, the $931 cash price and the $25 copay card floor were accurate, but list prices and program caps shift throughout the year.